HBM Healthcare Investments Reports Q2 2025 Results Amid Currency Fluctuations

In its quarterly report ending June 2025, HBM Healthcare Investments AG announced a moderate 0.5% increase in portfolio value in investment currencies. Yet, a strong Swiss franc led to an 8.4% NAV decline, translating to a CHF 140 million loss. The stock price also dropped by 5.5%.

Public companies saw a CHF 79 million loss due to adverse currency movements. Despite this, firms like Merus and ArriVent BioPharma reported promising clinical developments. Private company results were positive in investment currencies, but currency issues led to a CHF 33 million impairment.

No new investments were made this quarter, with a focus on follow-on investments in existing portfolio companies. The portfolio remains heavily tied to USD, EUR, and other currencies, leaving it vulnerable to fluctuations.

Looking ahead, HBM expects operational progress and strategic transactions from its portfolio despite market volatility and geopolitical uncertainties impacting sentiment.